Market Data
per eighth · AB 2402
Glass House Went 'Medical-Only' to Reach the NYSE — and Kept 90% of Its Stores' Profits
The $2.5 million deal that moved California's largest grower off its own dispensaries follows Trulieve's three-week-old playbook. But Kyle Kazan's real target isn't the opening bell — it's the export and interstate-commerce market that rescheduling just cracked open.
per eighth · AB 2402
Curaleaf Prints $70M as Green Thumb Rides Minnesota and Trulieve's Revenue Slips 4%
Three of the largest MSOs reported the first quarter under federal medical-cannabis rescheduling, and the prints split: Curaleaf's $70.1 million GAAP net income looks like a normal company's, while Trulieve's revenue still slipped 4% year-over-year. Analysts now watch the June 29 DEA hearing — and whether the divergence holds.
per eighth · AB 2402
280E Relief Lands: Trulieve Posts $287M Q1 Revenue and a 35% EBITDA Margin
The first quarter of post-rescheduling P&L visibility is here. Trulieve's medical-heavy revenue mix turns the Section 280E disallowance from a 70%-effective tax rate into a normal one. The market is repricing.